Volume 95 Issue 44 | p. 15 | Concentrates
Issue Date: November 6, 2017

Sumitomo licenses diabetes drug

Department: Business
Keywords: Drug development, diabetes, Poxel

Sumitomo Dainippon Pharma will pay $42 million up front for the right to develop Poxel’s type 2 diabetes treatment imeglimin in several Asian countries, including Japan and China. Poxel is in talks with Japanese regulators about the design of three Phase III studies slated to begin there by the end of this year. Poxel is looking for a partner to develop the compound in the U.S. and Europe. While currently marketed diabetes drugs modulate glucose levels, Poxel’s drug increases the amount of glucose excreted in urine.

 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment